Saturday 17 October 2026
Export IMNN’s income statement to Excel — free account
Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.02
0.04
−3.77%
Follow IMNN
Imunon, Inc. (IMNN) P/E ratio
Imunon, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 29.0× (June 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
Low 0.0×
High 29.0×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRAW Traws Pharma, Inc. compare | n/m |
| ENVB Enveric Biosciences, Inc. compare | n/m |
| EVGN Evogene Ltd. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| ORGS Orgenesis Inc. compare | n/m |
| CANF Can-Fite Biopharma Ltd compare | n/m |
| IMNN Imunon, Inc. | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)